{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T21:24:46Z","timestamp":1779917086351,"version":"3.53.1"},"reference-count":58,"publisher":"Japan Endocrine Society","issue":"2","funder":[{"DOI":"10.13039\/100030825","name":"Ascendis Pharma Denmark","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030825","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1507\/endocrj.ej25-0376","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T22:07:52Z","timestamp":1763417272000},"page":"275-289","source":"Crossref","is-referenced-by-count":1,"title":["Palopegteriparatide in Japanese adults with hypoparathyroidism: 52-week results from the phase 3 PaTHway Japan trial"],"prefix":"10.1507","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8753-6016","authenticated-orcid":false,"given":"Kenji","family":"Ashida","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Nomura","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5722-115X","authenticated-orcid":false,"given":"Noriko","family":"Makita","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Imanishi","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan"},{"name":"Vascular Science Center for Translational Research, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naotetsu","family":"Kanamoto","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Osaka City General Hospital, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Zhao","sequence":"additional","affiliation":[{"name":"Endocrine Medical Sciences, Ascendis Pharma Inc, Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Schneider","sequence":"additional","affiliation":[{"name":"Endocrine Medical Sciences, Ascendis Pharma Inc, Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Ukena","sequence":"additional","affiliation":[{"name":"Endocrine Medical Sciences, Ascendis Pharma Inc, Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryant","family":"Lai","sequence":"additional","affiliation":[{"name":"Endocrine Medical Sciences, Ascendis Pharma Inc, Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1801-5289","authenticated-orcid":false,"given":"Aimee D.","family":"Shu","sequence":"additional","affiliation":[{"name":"Endocrine Medical Sciences, Ascendis Pharma Inc, Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Toranomon Hospital, Tokyo, Japan"},{"name":"Okinaka Memorial Institute for Medical Research, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Shoback DM, Bilezikian JP, Costa AG, Dempster D, Dralle H, et al. (2016) Presentation of hypoparathyroidism: etiologies and clinical features. J Clin Endocrinol Metab 101: 2300\u20132312.","DOI":"10.1210\/jc.2015-3909"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Mannstadt M, Bilezikian JP, Thakker RV, Hannan FM, Clarke BL, et al. (2017) Hypoparathyroidism. Nat Rev Dis Primers 3: 17055.","DOI":"10.1038\/nrdp.2017.55"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Kontogeorgos G, Mamasoula Z, Krantz E, Trimpou P, Landin-Wilhelmsen K, et al. (2022) Low health-related quality of life in hypoparathyroidism and need for PTH analog. Endocr Connect 11: e210379.","DOI":"10.1530\/EC-21-0379"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Brod M, Waldman LT, Smith A, Karpf D (2021) Living with hypoparathyroidism: development of the hypoparathyroidism patient experience scale-impact (HPES-Impact). Qual Life Res 30: 277\u2013291.","DOI":"10.1007\/s11136-020-02607-1"},{"key":"5","doi-asserted-by":"crossref","first-page":"ziae100","DOI":"10.1093\/jbmrpl\/ziae100","volume":"8","author":"M Hasegawa","year":"2024","unstructured":"5 Hasegawa M, Sakakibara Y, Takeuchi Y, Sugitani I, Ozono K, et al. (2024) Prevalence and characteristics of postoperative and nonoperative chronic hypoparathyroidism in Japan: a nationwide retrospective analysis. JBMR Plus 8: ziae100.","journal-title":"JBMR Plus","ISSN":"https:\/\/id.crossref.org\/issn\/2473-4039","issn-type":"print"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6 Teshima M, Otsuki N, Morita N, Furukawa T, Shinomiya H, et al. (2018) Postoperative hypoparathyroidism after total thyroidectomy for thyroid cancer. Auris Nasus Larynx 45: 1233\u20131238.","DOI":"10.1016\/j.anl.2018.04.008"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Clarke BL, Brown EM, Collins MT, J\u00fcppner H, Lakatos P, et al. (2016) Epidemiology and diagnosis of hypoparathyroidism. J Clin Endocrinol Metab 101: 2284\u20132299.","DOI":"10.1210\/jc.2015-3908"},{"key":"8","unstructured":"8 Michigami T (2016) Pathophysiology of hypoparathyroidism. Clin Calcium 26: 831\u2013838 (In Japanese)."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Takatani R, Kubota T, Minagawa M, Inoue D, Fukumoto S, et al. (2023) Prevalence of pseudohypoparathyroidism and nonsurgical hypoparathyroidism in Japan in 2017: a nationwide survey. J Epidemiol 33: 569\u2013573.","DOI":"10.2188\/jea.JE20220152"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10 Takeuchi Y (2018) Parathyroid diseases and metabolic bone diseases. Official Journal of the Japan Association of Endocrine Surgeons and the Japanese Society of Thyroid Surgery 35: 263\u2013267 (In Japanese).","DOI":"10.11226\/jaesjsts.35.4_263"},{"key":"11","unstructured":"11 Minagawa M (2017) Update on recent progress in vitamin D research. Vitamin D treatment for hypoparathyroidism. Clin Calcium 27: 1623\u20131628 (In Japanese)."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Khan AA, Bilezikian JP, Brandi ML, Clarke BL, Gittoes NJ, et al. (2022) Evaluation and management of hypoparathyroidism summary statement and guidelines from the second international workshop. J Bone Miner Res 37: 2568\u20132585.","DOI":"10.1002\/jbmr.4691"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Khan AA, Koch CA, Van Uum S, Baillargeon JP, Bollerslev J, et al. (2019) Standards of care for hypoparathyroidism in adults: a Canadian and International Consensus. Eur J Endocrinol 180: P1\u2013P22.","DOI":"10.1530\/EJE-18-0609"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Gosmanova EO, Houillier P, Rejnmark L, Marelli C, Bilezikian JP (2021) Renal complications in patients with chronic hypoparathyroidism on conventional therapy: a systematic literature review: renal disease in chronic hypoparathyroidism. Rev Endocr Metab Disord 22: 297\u2013316.","DOI":"10.1007\/s11154-020-09613-1"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Ogata E (1990) Hypoparathyroidism: practice and theoretical backgrounds for 1 alpha(OH)D3 treatment. Bone Miner 9: 229\u2013232.","DOI":"10.1016\/0169-6009(90)90040-M"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Hadker N, Egan J, Sanders J, Lagast H, Clarke BL (2014) Understanding the burden of illness associated with hypoparathyroidism reported among patients in the PARADOX study. Endocr Pract 20: 671\u2013679.","DOI":"10.4158\/EP13328.OR"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Buttner M, Musholt TJ, Singer S (2017) Quality of life in patients with hypoparathyroidism receiving standard treatment: a systematic review. Endocrine 58: 14\u201320.","DOI":"10.1007\/s12020-017-1377-3"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Zavatta G, Clarke BL (2020) Challenges in the management of chronic hypoparathyroidism. Endocr Connect 9: R229\u2013R240.","DOI":"10.1530\/EC-20-0366"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Karpf DB, Pihl S, Mourya S, Mortensen E, Kovoor E, et al. (2020) A randomized double-blind placebo-controlled first-in-human phase 1 trial of transcon PTH in healthy adults. J Bone Miner Res 35: 1430\u20131440.","DOI":"10.1002\/jbmr.4016"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Holten-Andersen L, Pihl S, Rasmussen CE, Zettler J, Maitro G, et al. (2019) Design and preclinical development of TransCon PTH, an investigational sustained-release PTH replacement therapy for hypoparathyroidism. J Bone Miner Res 34: 2075\u20132086.","DOI":"10.1002\/jbmr.3824"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Ahmed I, Eriksen E, Hofbauer L, Khan A, Le J, et al. (2022) OR21-1 the PaTH forward trial: efficacy and safety of TransCon PTH through week 84 for adults with hypoparathyroidism. J Endocr Soc 6: A193.","DOI":"10.1210\/jendso\/bvac150.398"},{"key":"22","unstructured":"22 (2023) Yorvipath (palopegteriparatide). https:\/\/ema.europa.eu\/en\/medicines\/human\/EPAR\/yorvipath accessed on October 1, 2025."},{"key":"23","unstructured":"23 (2024) Yorvipath (palopegteriparatide) [Prescribing Information]. https:\/\/yorvipathhcp.com\/pdf\/yorvipath_pi.pdf accessed on October 1, 2025."},{"key":"24","unstructured":"24 (2024) Yorvipath (palopegteriparatide) (PLGB 51127\/0001-0003). Marketing authorisations granted 15 April 2024 to 30 April 2024. https:\/\/assets.publishing.service.gov.uk\/media\/663df12eae748c43d37938de\/marketing-authorisations-granted-15-to_30-april-2024.pdf accessed on October 1, 2025."},{"key":"25","unstructured":"25 (2025) Australian public assessment report for YORVIPATH (Active ingredient: Palopegteriparatide). https:\/\/tga.gov.au\/sites\/default\/files\/2025-08\/auspar-yorvipath-250801.pdf accessed on October 1, 2025."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Khan AA, Rubin MR, Schwarz P, Vokes T, Shoback DM, et al. (2023) Efficacy and safety of parathyroid hormone replacement with TransCon PTH in hypoparathyroidism: 26-week results from the phase 3 PaTHway trial. J Bone Miner Res 38: 14\u201325.","DOI":"10.1002\/jbmr.4726"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Clarke BL, Khan AA, Rubin MR, Schwarz P, Vokes T, et al. (2025) Efficacy and safety of TransCon PTH in adults with hypoparathyroidism: 52-week results from the phase 3 PaTHway trial. J Clin Endocrinol Metab 110: 951\u2013960.","DOI":"10.1210\/clinem\/dgae693"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Fukui A, Yokoo T, Nangaku M, Kashihara N (2019) New measures against chronic kidney diseases in Japan since 2018. Clin Exp Nephrol 23: 1263\u20131271.","DOI":"10.1007\/s10157-019-01786-7"},{"key":"29","doi-asserted-by":"publisher","unstructured":"29 Zhang R, Wang Z, Fei Y, Zhou B, Zheng S, et al. (2015) The difference in nutrient intakes between Chinese and Mediterranean, Japanese and American Diets. Nutrients 7: 4661\u20134688.","DOI":"10.3390\/nu7064661"},{"key":"30","unstructured":"30 Maruish M, Maruish M, Kosinski M, Bjorner JB, Gandek B, et al. (2011) User\u2019s manual for the SF-36v2 health survey."},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, et al. (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53: 982\u2013992.","DOI":"10.1053\/j.ajkd.2008.12.034"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Ku E, Xie D, Shlipak M, Hyre Anderson A, Chen J, et al. (2016) Change in Measured GFR <i>Versus<\/i> eGFR and CKD Outcomes. J Am Soc Nephrol 27: 2196\u20132204.","DOI":"10.1681\/ASN.2015040341"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Mayne TJ, Nordyke RJ, Schold JD, Weir MR, Mohan S (2021) Defining a minimal clinically meaningful difference in 12-month estimated glomerular filtration rate for clinical trials in deceased donor kidney transplantation. Clin Transplant 35: e14326.","DOI":"10.1111\/ctr.14326"},{"key":"34","unstructured":"34 Kanis JA on behalf of the World Health Organization Scientific Group (2007) Assessment of osteoporosis at the primary health-care level. Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK."},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Carey JJ, Delaney MF, Love TE, Richmond BJ, Cromer BA, et al. (2007) DXA-generated Z-scores and T-scores may differ substantially and significantly in young adults. J Clin Densitom 10: 351\u2013358.","DOI":"10.1016\/j.jocd.2007.06.001"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, et al. (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19: 331\u2013337.","DOI":"10.1007\/s007740170001"},{"key":"37","doi-asserted-by":"publisher","unstructured":"37 Shishiba Y, Imai T, Kanmori M, Kurihara H, Tori M, et al. (2017) Prevalence of postsurgical hypoparathyroidism in Japan: estimated from the data of multiple institutes. Official Journal of the Japan Association of Endocrine Surgeons and the Japanese Society of Thyroid Surgery 34: 51\u201356 (In Japanese).","DOI":"10.11226\/jaesjsts.34.1_51"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Nakamura Y, Matsumoto T, Tamakoshi A, Kawamura T, Seino Y, et al. (2000) Prevalence of idiopathic hypoparathyroidism and pseudohypoparathyroidism in Japan. J Epidemiol 10: 29\u201333.","DOI":"10.2188\/jea.10.29"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Clarke B, Hofbauer L, Khan A, Schwarz P, Jain R, et al. (2023) Abstract #1408044: long-term efficacy and safety of TransCon PTH from phase 2 PaTH forward trial in adults with chronic hypoparathyroidism. Endocr Pract 29: S58.","DOI":"10.1016\/j.eprac.2023.03.132"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Shimatsu A, Tai S, Imori M, Ihara K, Taketsuna M, et al. (2013) Efficacy and safety of growth hormone replacement therapy in Japanese adults with growth hormone deficiency: a post-marketing observational study. Endocr J 60: 1131\u20131144.","DOI":"10.1507\/endocrj.EJ13-0083"},{"key":"41","unstructured":"41 Herdman M (2023) Using patient reported outcome measures in a cross-cultural context: conceptual and linguistic issues. https:\/\/ispor.org\/docs\/default-source\/presentations\/961.pdf?sfvrsn=7c01dc5a_1 accessed on October 1, 2025."},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Gosmanova EO, Chen K, Rejnmark L, Mu F, Swallow E, et al. (2021) Risk of chronic kidney disease and estimated glomerular filtration rate decline in patients with chronic hypoparathyroidism: a retrospective cohort study. Adv Ther 38: 1876\u20131888.","DOI":"10.1007\/s12325-021-01658-1"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43 Noori W, Inguva S, Sibley CT, Chirikov V, Smith AR (2023) SAT233 clinical and economic burden of postsurgical chronic hypoparathyroidism: a US medicare retrospective analysis. J Endocr Soc 7: bvad114.529.","DOI":"10.1210\/jendso\/bvad114.529"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Rejnmark L, Ayodele O, Lax A, Mu F, Swallow E, et al. (2023) The risk of chronic kidney disease development in adult patients with chronic hypoparathyroidism treated with rhPTH (1\u201384): A retrospective cohort study. Clin Endocrinol (Oxf) 98: 496\u2013504.","DOI":"10.1111\/cen.14813"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 Kawai Y, Uneda K, Miyata S, Kunii A, Nagayama S, et al. (2024) A pharmacovigilance study on clinical factors of active vitamin D(3) analog-related acute kidney injury using the Japanese Adverse Drug Event Report Database. Sci Rep 14: 21356.","DOI":"10.1038\/s41598-024-72505-w"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46 Shoback D (2008) Clinical practice. Hypoparathyroidism. N Engl J Med 359: 391\u2013403.","DOI":"10.1056\/NEJMcp0803050"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47 Underbjerg L, Sikjaer T, Rejnmark L (2018) Long-term complications in patients with hypoparathyroidism evaluated by biochemical findings: a case-control study. J Bone Miner Res 33: 822\u2013831.","DOI":"10.1002\/jbmr.3368"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48 Khan AA, Bilezikian JP, Brandi ML, Clarke BL, Potts JJ, et al. (2022) The second international workshop on the evaluation and management of hypoparathyroidism. J Bone Miner Res 37: 2566\u20132567.","DOI":"10.1002\/jbmr.4671"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49 Ayodele O, Rejnmark L, Mu F, Lax A, Berman R, et al. (2022) Five-year estimated glomerular filtration rate in adults with chronic hypoparathyroidism treated with rhPTH (1\u201384): a retrospective cohort study. Adv Ther 39: 5013\u20135024.","DOI":"10.1007\/s12325-022-02292-1"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50 Chen KS, Gosmanova EO, Curhan GC, Ketteler M, Rubin M, et al. (2020) Five-year estimated glomerular filtration rate in patients with hypoparathyroidism treated with and without rhPTH (1\u201384). J Clin Endocrinol Metab 105: e3557\u2013e3565.","DOI":"10.1210\/clinem\/dgaa490"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51 Rejnmark L, Gosmanova EO, Khan AA, Makita N, Imanishi Y, et al. (2024) Palopegteriparatide treatment improves renal function in adults with chronic hypoparathyroidism: 1-year results from the phase 3 PaTHway trial. Adv Ther 41: 2500\u20132518.","DOI":"10.1007\/s12325-024-02843-8"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52 Rambausek M, Ritz E, Rascher W, Kreusser W, Mann JF, et al. (1982) Vascular effects of parathyroid hormone (PTH). Adv Exp Med Biol 151: 619\u2013632.","DOI":"10.1007\/978-1-4684-4259-5_64"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53 Grant FD, Mandel SJ, Brown EM, Williams GH, Seely EW (1992) Interrelationships between the renin-angiotensin-aldosterone and calcium homeostatic systems. J Clin Endocrinol Metab 75: 988\u2013992.","DOI":"10.1210\/jcem.75.4.1400892"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54 Wang HH, Drugge ED, Yen YC, Blumenthal MR, Pang PK (1984) Effects of synthetic parathyroid hormone on hemodynamics and regional blood flows. Eur J Pharmacol 97: 209\u2013215.","DOI":"10.1016\/0014-2999(84)90452-7"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55 Aloia JF, Arunabh-Talwar S, Pollack S, Yeh JK (2008) The remodeling transient and the calcium economy. Osteoporos Int 19: 1001\u20131009.","DOI":"10.1007\/s00198-007-0542-6"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56 Clarke B, Khan A, Rubin M, Schwarz P, Vokes T, et al. (2023) Long-term efficacy and safety of transcon PTH in adults with hypoparathyroidism: 52-week results from the open-label extension of the phase 3 pathway trial. J Endocr Soc 7: bvad114.563.","DOI":"10.1210\/jendso\/bvad114.563"},{"key":"57","unstructured":"57 labcorp (2025). https:\/\/www.labcorp.com\/tests\/140850\/intact-n-terminal-propeptide-of-type-1-procollagen. accessed on October 28, 2025."},{"key":"58","doi-asserted-by":"crossref","unstructured":"58 Silva BC, Leslie WD, Resch H, Lamy O, Lesnyak O, et al. (2014) Trabecular bone score: a noninvasive analytical method based upon the DXA image. J Bone Miner Res 29: 518\u2013530.","DOI":"10.1002\/jbmr.2176"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/73\/2\/73_EJ25-0376\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T03:25:16Z","timestamp":1770434716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/73\/2\/73_EJ25-0376\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej25-0376","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"EJ25-0376"}}